Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.

Luis M. Blanco-Colio, Jose L. Martín-Ventura, Eduardo de Teresa, Csaba Farsang, Allan Gaw, Gianfranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Jesús Egido

Research output: Contribution to journalArticle

Abstract

The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P

Original languageEnglish
JournalKidney international. Supplement
Issue number111
Publication statusPublished - Dec 2008

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.'. Together they form a unique fingerprint.

  • Cite this

    Blanco-Colio, L. M., Martín-Ventura, J. L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., & Egido, J. (2008). Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney international. Supplement, (111).